- $1.55bn
- $874.80m
- $125.60m
- 68
- 31
- 99
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 3.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.29% | ||
| Return on Equity | -62.22% | ||
| Operating Margin | -1618.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 14.61 | 55.55 | 93.11 | 125.59 | 147.17 | 177.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 11th, 2020
- Public Since
- June 12th, 2024
- No. of Shareholders
- 463
- No. of Employees
- 1,000
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 35,973,494
- Address
- 1525 O'brien Drive, MENLO PARK, 94025
- Web
- https://grail.com/
- Phone
- +1 6507719796
- Contact
- Alex Dobbin
- Auditors
- Ernst & Young LLP
Upcoming Events for GRAL
Q3 2025 Grail Inc Earnings Release
Similar to GRAL
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Grail share price?
As of Today at 17:38 UTC, shares in Grail are trading at $43.95. This share price information is delayed by 15 minutes.
How has the Grail share price performed this year?
Shares in Grail last closed at $43.95 and the price had moved by +135.91% over the past 365 days. In terms of relative price strength the Grail share price has outperformed the S&P500 Index by +111.79% over the past year.
What are the analyst and broker recommendations for Grail?
The overall consensus recommendation for Grail is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Grail dividend yield?
Grail does not currently pay a dividend.
Does Grail pay a dividend?
Grail does not currently pay a dividend.
When does Grail next pay dividends?
Grail does not currently pay a dividend.
How do I buy Grail shares?
To buy shares in Grail you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Grail?
As of the previous close price of $43.95, shares in Grail had a market capitalisation of $1.58bn.
Where are Grail shares listed?
Here are the trading details for Grail:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GRAL
What kind of share is Grail?
Based on an overall assessment of its quality, value and momentum Grail is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Grail share price forecast for 2025?
The analyst consensus target price for shares in Grail is $31.50. That is 28.33% below the last closing price of $43.95.
Analysts covering Grail currently have a consensus Earnings Per Share (EPS) forecast of -$14.74 for the next financial year.
Find out moreWhat is the trend in the Grail share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Grail. Over the past six months, its share price has outperformed the S&P500 Index by +121.92%.
As of the last closing price of $43.95, shares in Grail were trading +69.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Grail PE Ratio?
The Grail PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $43.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Grail?
We do not have data on Grail's directors